| abstract |
In the present invention, an N- (azaaryl) cyclolactam-1-carboxamide derivative having a structure of formula (I), its synthesis method and its use are presented. Each substituent is defined in the specification and claims. The series of compounds presented in the present invention are cancer, tumor, autoimmune disease, metabolic or metastatic disease, in particular ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease It can be widely used in the preparation of primary metastatic tumor or metastatic bone cancer therapeutics and is expected to be developed as next generation CSF-1R inhibitor. |